$0.70
30.73% yesterday
Nasdaq, Jun 13, 10:18 pm CET
ISIN
US92243A2006
Symbol
VXRT
Sector
Industry

Vaxart, Inc. Stock price

$0.70
+0.29 68.95% 1M
+0.11 18.58% 6M
+0.04 6.03% YTD
-0.05 6.39% 1Y
-1.76 71.46% 5Y
-21.85 96.89% 10Y
-328.90 99.79% 20Y
Nasdaq, Closing price Fri, Jun 13 2025
+0.17 30.73%
ISIN
US92243A2006
Symbol
VXRT
Sector
Industry

Key metrics

Market capitalization $160.27m
Enterprise Value $122.07m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 2.58
P/S ratio (TTM) P/S ratio 3.38
P/B ratio (TTM) P/B ratio 3.51
Revenue growth (TTM) Revenue growth 433.18%
Revenue (TTM) Revenue $47.40m
EBIT (operating result TTM) EBIT $-57.16m
Free Cash Flow (TTM) Free Cash Flow $-33.73m
Cash position $41.94m
EPS (TTM) EPS $-0.27
P/E forward negative
P/S forward 7.42
EV/Sales forward 5.65
Short interest 6.51%
Show more

Is Vaxart, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,847 stocks worldwide.

Vaxart, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

3 Analysts have issued a Vaxart, Inc. forecast:

3x Buy
100%

Analyst Opinions

3 Analysts have issued a Vaxart, Inc. forecast:

Buy
100%

Financial data from Vaxart, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
47 47
433% 433%
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 19 19
20% 20%
39%
- Research and Development Expense 86 86
27% 27%
181%
-48 -48
34% 34%
-102%
- Depreciation and Amortization 8.92 8.92
2% 2%
19%
EBIT (Operating Income) EBIT -57 -57
30% 30%
-121%
Net Profit -58 -58
29% 29%
-123%

In millions USD.

Don't miss a Thing! We will send you all news about Vaxart, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Vaxart, Inc. Stock News

Neutral
GlobeNewsWire
about 19 hours ago
SOUTH SAN FRANCISCO, Calif., June 13, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) (“Vaxart” or the “Company”), a clinical-stage biotechnology company developing a range of oral recombinant pill vaccines based on its proprietary delivery platform, today held its Annual Meeting of Stockholders (the “Annual Meeting”) in a virtual-only format. Preliminary results from the Annual Meeting in...
Neutral
GlobeNewsWire
3 days ago
- Second-generation norovirus constructs produce statistically significant increases in GI.1 and GII.4 norovirus blocking antibodies (141% and 94%, respectively) compared with first-generation constructs, supporting potential for improved protection against infection -
Neutral
GlobeNewsWire
4 days ago
SOUTH SAN FRANCISCO, Calif., June 10, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. (NASDAQ: VXRT), a clinical-stage biotechnology company developing a range of oral recombinant pill vaccines based on its proprietary delivery platform, today announced it will release topline data from the norovirus Phase I trial before the market open on Wednesday, June 11, 2025. The Vaxart senior management team will ...
More Vaxart, Inc. News

Company Profile

Biota Holdings Pty Ltd. operates as an anti infective drug development firm. The company was founded on October 2, 1985 and is headquartered in Notting Hil, Australia.

Head office United States
CEO Steven Lo
Employees 105
Founded 2004
Website vaxart.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today